Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples

Gut

Volumn 53, Issue 12, 2004, Pages 1860-1865

  Khalid, A ^a,b   Pal, R ^c   Sasatomi, E ^c   Swalsky, P ^c   Slivka, A ^b   Whitcomb, D ^b   Finkelstein, S ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ARTICLE; BILE DUCT OBSTRUCTION; BILIARY TRACT CANCER; BINDING SITE; CANCER CYTODIAGNOSIS; CELL LINEAGE; CELL STRUCTURE; CLINICAL ARTICLE; CLONAL VARIATION; CODON; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC LINKAGE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; MICRODISSECTION; MICROSATELLITE MARKER; ONCOGENE K RAS; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SURGICAL TECHNIQUE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; BILE DUCT NEOPLASMS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CYTODIAGNOSIS; DNA MUTATIONAL ANALYSIS; GENES, RAS; GENOTYPE; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; PANCREATIC NEOPLASMS;

EID: 9344237719     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.039784     Document Type: Article

References (51)

1. Stewart CJ, Mills PR, Carter R, et al. Brush cytology in the assessment of pancreatico-biliary strictures: a review of 406 cases. J Clin Pathol 2001;54:449-55.
2. Pugliese V, Pujic N, Saccomanno S, et al. Pancreatic intraductal sampling during ERCP in patients with chronic pancreatitis and pancreatic cancer: cytologic studies and k-ras-2 codon 12 molecular analysis in 47 cases. Gastrointest Endosc 2001;54:595-9.
3. Farrell RJ, Jain AK, Brandwein SL, et al. The combination of stricture dilation, endoscopic needle aspiration, and biliary brushings significantly improves diagnostic yield from malignant bile duct strictures. Gastrointest Endosc 2001;54:587-94.
4. Macken E, Drijkoningen M, Van Aken E, et al. Brush cytology of ductal strictures during ERCP. Acta Gastroenterol Belg 2000;63:254-9.
5. Glasbrenner B, Ardan M, Boeck W, et al. Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography. Endoscopy 1999;31:712-17.
6. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001;25:579-86.
7. Apple SK, Hecht JR, Lewin DN, et al. Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol 1999;30:123-9.
8. Schmid RM. Genetic basis of pancreatic cancer. Balliers Best Pract Res Clin Gastroenterol 2002;16:421-33.
9. Rozenblum E, Schutte M, Goggins M, et al. Tumor suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4.
10. Mizumoto K, Tanaka M. Genetic diagnosis of pancreatic cancer. J Hepatobiliary Pancreat Surg 2002;9:39-44.
11. Griffin CA, Hruban RH, Morsberger LA, et al. Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res 1995;55:2394-9.
12. Rashid A. Cellular and molecular biology of biliary tract cancers. Surg Oncol Clin N Am 2002;11:995-100.
13. Ku JL, Yoon KA, Kim IJ, et al. Establishment and characterization of six human biliary tract cancer cell lines. Br J Cancer 2002;87:187-93.
14. Kang YK, Kim YI, Kim WH. Allelotype analysis of intrahepatic cholangiocarcinoma. Mod Pathol 2000;13:627-31.
15. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
16. Caldas C, Kern SE. K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 1995;18:1-6.
17. Motojima K, Tsunoda T, Kanematsu T, et al. Distinguishing pancreatic carcinoma from other periampullary carcinomas by analysis of mutations in the Kirsten-ras oncogene. Ann Surg 1991;214:657-62.
18. Tsuda H, Satarug S, Bhudhisawasdi V, et al. Cholangiocarcinomas in Japanese and Thai patients: difference in etiology and incidence of paint mutation of the c-Ki-ras proto-oncogene. Mol Carcinog 1992;6:266-9.
19. Boschman CR, Stryker S, Reddy JK, et al. Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. Am J Pathol 1994;145:1291-5.
20. Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-33.
21. Barton CM, Staddon SL, Hughes CM, et al. Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer 1991;64:1076-82.
22. Biankin AV, Kench JG, Morey AL, et al. Overexpression of p21 (WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res 2001;61:8830-7.
23. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
24. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995;333:970-4.
25. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60:2002-6.
26. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
27. Luttges J, Galehdari H, Brocker V, et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 2001;158:1677-83.
28. Taniai M, Higuchi H, Burgart U, et al. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002;123:1090-8.
29. Isa T, Tomita S, Nakachi A, et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2002;49:604-8.
30. Ahrendt SA, Rashid A, Chow JT, et al. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Surg 2000;7:426-31.
31. Ding SF, Delhanty JD, Bowles L, et al. Loss of constitutional heterozygosity on chromosomes 5 and 17 in cholangiocarcinoma. Br J Cancer 1993;67:1007-10.
32. Kang YK, Kim WH, Lee HW, et al. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 1999;79:477-83.
33. Kiba T, Tsuda H, Pairojkul C, et al. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Mol Carcinog 1993;8:312-18.
34. Levi S, Urbano-Ispizua A, Gill R, et al. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 1991;51:3497-502.
35. Ohashi K, Nakajima Y, Kanehiro H, et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology 1995;109:1612-17.
36. Tada M, Omata M, Ohto M. High incidence of ras gene mutation in intrahepatic cholangiocarcinoma. Cancer 1992;69:1115-18.
37. INK4B/MTS2 genes in biliary tract cancers. Cancer Res 1995;55:2756-60.
38. Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol 2000;156:18215.
39. Khalid A, Whitcomb DC. The premalignant lesions for pancreatic cancer; will Pan-IN's pan out? Gastroenterology 2002;123:645-7.
40. Solcia E, Capella C, Kloppel G. Tumors of the pancreas, atlas of tumor pathology. Washington DC: Armed Forces Institute of Pathology, American Registry of Pathology, 1997.
41. Hawkins TL, Detter JC, Richardson PM. Whole genome amplification - applications and advances. Curr Opin Biotechnol 2002;13:65-7.
42. Barbaux S, Poirier O, Combien F. Use of degenerate oligonucleotide primed PCR (DOP-PCR) for the genotyping of low-concentration DNA samples. J Mol Med 2001;79:329-32.
43. Larsen J, Ottesen AM, Lundsteen C, et al. Optimization of DOP-PCR amplification of DNA for high-resolution comparative genomic. Cytometry 2001;44:317.
44. Rolston R, Sasatomi E, Hunt J, et al. Distinguishing de novo second cancer formation from tumor recurrence: mutational fingerprinting by microdissection genotyping. J Mol Diagn 2001;3:129-32.
45. Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science 1989;244:217-21.
46. van Heek T, Rader AE, Offerhaus GJ, et al. K-ras, p53, and DPC4 (MAD4) alterations In fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. Am J Clin Pathol 2002;117:755-65.
47. Gorunova L, Hoglund M, Andren-Sandberg A, et al. Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes Cance 1998;23:8199.
48. Harada T, Okita K, Shiraishi K, et al. Interglandular cytogenetic heterogeneity detected by comparative genomic hybridization in pancreatic cancer. Cancer Res 2002;62:8359.
49. Ohori P, Khalid A, Etemad B, et al. Multiple loss of heterozygosity without k-ras mutation identified by molecular analysis on fine needle aspiration cytology specimen of acinar cell carcinoma of pancreas. Diagn Cytopathol 2002;27:42-6.
50. Tada M, Omata M, Kawai S, et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993;53:2472-4.
51. Tada M, Ohashi M, Shiratori Y, et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 1996;10:227-31.